Heart failure is a leading cause of morbidity and mortality globally. The natural history of
heart failure with reduced ejection fraction (HFrEF) has been altered with the development of …

This is a time of great advancement in the care of patients with heart failure with reduced
ejection fraction (HFrEF). A recent entry on the list of drugs that reduce mortality in patients …

This Focus Issue on heart failure and cardiomyopathies contains the '2021 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure'. 1 These Guidelines are …

Heart failure with reduced ejection fraction (HFrEF) requires a multimodal treatment with
combination of several drugs as the cornerstone for symptomatic and prognostic …

(HFpEF) has been traditionally thought of as a complex and heterogenous disease—a
disease with multiple patient phenotypes that span the spectrum from the “little old lady” with …

Possibly no recent heart failure clinical trial's top-line results have led to a greater collective
sigh of relief nor the abrupt unveiling of the proverbial “mission accomplished” banner than …

Approximately 3 decades ago, the standard of care for patients with heart failure with
reduced ejection fraction was digoxin and diuretics. 1 The path to defining guideline …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

The landscape of clinical trials for heart failure with preserved ejection fraction (HFpEF) is
littered with failed therapies, in stark contrast with that for heart failure with reduced ejection …

Multiple clinical trials have demonstrated the benefit of sodium-glucose cotransporter-2
(SGLT2) inhibitor therapy among patients with heart failure (HF). 1 Dapagliflozin and …